{"id":200416,"date":"2026-08-13T11:32:16","date_gmt":"2026-08-13T06:02:16","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=200416"},"modified":"2026-08-13T11:32:19","modified_gmt":"2026-08-13T06:02:19","slug":"aarti-drugs-vs-morepen-laboratories","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/aarti-drugs-vs-morepen-laboratories\/","title":{"rendered":"Aarti Drugs vs Morepen Laboratories: Share Price, PE and ROE Compared"},"content":{"rendered":"
<\/div>\n

Aarti Drugs MCap Rs 3,940 Cr, PE 20.61x, ROE 12.58%. Morepen Laboratories MCap Rs 4,030 Cr, PE 28.62x, ROE 5.96%.<\/em><\/p>\n

\n

Quick Answer<\/strong><\/p>\n

Aarti Drugs and Morepen Laboratories are small-cap pharma API companies with near-identical market caps around Rs 4,000 Cr. Aarti Drugs at PE 20.61x with ROE 12.58% is more attractively priced than Morepen at PE 28.62x with ROE 5.96%. Aarti focuses on generic APIs; Morepen has an OTC consumer health business alongside APIs.<\/p>\n<\/div>\n

The Aarti Drugs vs Morepen Laboratories question comes up often among investors who follow the Pharma API space in India. Aarti Drugs MCap Rs 3,940 Cr, PE 20. 61x, ROE 12. This article goes through what each company does, their latest financial performance, and the key numbers that matter for anyone evaluating Aarti Drugs vs Morepen Laboratories as a research exercise.<\/p>\n

All data cited here is sourced from publicly available company filings. Verify the latest prices and fundamentals on NSE or BSE before acting on any information.<\/p>\n

\n
\n

Table of Contents<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n